# A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the Blood

> **NCT03082183** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** BI 425809

## Key facts

- **NCT ID:** NCT03082183
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-28
- **Primary completion:** 2017-06-20
- **Final completion:** 2017-06-20
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03082183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03082183, "A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the Blood". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03082183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*